Cancer Family
Intraepithelial Neoplasia
CI-CAN-00000210Explore in graph →
Non-malignant79 active trials
- NCIt
- C8366
Loading cancer entity…
Cancer Family
CI-CAN-00000210Explore in graph →
Clinical trials
491 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06949800 | CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial | recruiting | Phase 2 | 90 | University of California, San FranciscoOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer(SWIFT) | not yet recruiting | Phase 2 | 48 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02397083 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer(LEVER) | active not recruiting | Phase 2 | 102 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05316935 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | recruiting | Phase 2 / Phase 3 | 80 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | recruiting | Phase 2 / Phase 3 | 29 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07545746 | Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya(ASCEND) | not yet recruiting | Phase 2 | 140 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer(MELIA) | not yet recruiting | Phase 2 | 128 | Tongji HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07669363 | Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)(Aurora) | not yet recruiting | Phase 2 | 230 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03603808 | VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | completed | Phase 2 | 44 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 8, 2026 | clinicaltrials |
| NCT03671811 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | active not recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07572396 | Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities | recruiting | Phase 2 | 45 | Amplexd Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07454915 | PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia | recruiting | Phase 2 | 138 | PapiVax Biotech, Inc.OTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH(2026ColECFerSp) | recruiting | Phase 2 | 30 | Wang JianliuOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04712851 | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | completed | Phase 1 / Phase 2 | 224 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05502367 | A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | terminated | Phase 1 / Phase 2 | 44 | Antiva BiosciencesINDUSTRY | 3 | Feb 19, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02882282 | Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04098744 | Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)(ART-CIN_IIB) | recruiting | Phase 2 | 78 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03300557 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06075264 | Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)(ART-VIN IIB) | recruiting | Phase 2 | 27 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07095478 | Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer(NeoART-CIN) | not yet recruiting | Phase 2 | 28 | Metanoic Health Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05104099 | Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia(PhotodiVIN) | completed | Phase 2 | 17 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05555862 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL(anal HSIL HIV-) | active not recruiting | Phase 2 | 17 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03267680 | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT06525870 | Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial(Trichlosil) | unknown | Phase 2 | 44 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06601205 | Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.(2F) | completed | Phase 2 / Phase 3 | 125 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05675787 | Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia | unknown | Phase 2 | 82 | Peking University People's HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03911076 | Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL(PVX2) | terminated | Phase 2 | 16 | PapiVax Biotech, Inc.OTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02864147 | Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) | completed | Phase 2 | 134 | Yale UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT02481414 | A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions | completed | Phase 2 | 81 | University of ArkansasOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06015854 | Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II(Vvax) | unknown | Phase 2 | 18 | University Medical Center GroningenOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT02740777 | Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females | completed | Phase 2 | 900 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02529930 | An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | completed | Phase 1 / Phase 2 | 34 | Nykode Therapeutics ASAINDUSTRY | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03113942 | Study of Pomalidomide in Anal Cancer Precursors(SPACE) | unknown | Phase 2 | 26 | Kirby InstituteOTHER_GOV | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03463252 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | recruiting | Phase 2 / Phase 3 | 224 | West China Second University HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03937791 | Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2021 | clinicaltrials |
| NCT03233412 | Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions | completed | Phase 2 | 90 | Barretos Cancer HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04650711 | Immunohistochemical Staining of p16 for the Screening of Cervical Cancer | unknown | Phase 2 | 250 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT01925378 | A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 12, 2020 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials